Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LNG Energy Group Corp. V.LNGE

Alternate Symbol(s):  V.LNGE.W | LNGNF

Energy Oil & Gas E&P
LNG Energy Group Corp is a Canada-based company, which is focused on the acquisition and development of natural gas production and exploration assets in Latin America. The Company’s assets include Sinu-San Jacinto-1(SSJN-1), Valle Inferior del Magdelana-41 (VIM-41), Valle Inferior del Magdalena-42 (VIM-42) and Sinu-San Jacinto 3-1(SSJN 3-1). The Company has a 50% working interest in SSJN-1, VIM... see more

Recent & Breaking News (TSXV:LNGE)

OTC Markets Group Welcomes Mind Cure Health Inc. to OTCQX

PR Newswire September 30, 2021

MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

PR Newswire September 28, 2021

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

PR Newswire September 27, 2021

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

PR Newswire September 23, 2021

MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF

PR Newswire September 22, 2021

MINDCURE to Participate in Maxim Group LLC's Advances in Mental Health Virtual Conference

PR Newswire September 17, 2021

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

PR Newswire September 16, 2021

MINDCURE Announces Platinum Sponsorship of the 2021 SANA Symposium

PR Newswire September 9, 2021

MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire September 8, 2021

MINDCURE Announces Financial Results for Fiscal 2021

PR Newswire August 31, 2021

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America

PR Newswire August 26, 2021

MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team

PR Newswire August 10, 2021

MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor

PR Newswire August 4, 2021

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

PR Newswire July 27, 2021

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

PR Newswire July 13, 2021

MINDCURE Adopts Advance Notice Policy

PR Newswire July 12, 2021

Maxim Group Initiates Coverage of Mind Cure Health

PR Newswire June 30, 2021

MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

Canada NewsWire June 17, 2021

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Canada NewsWire June 3, 2021

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Canada NewsWire May 20, 2021